Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re starting the day off right with a dive into the biggest pre-market stock movers for Wednesday! Source: ventdusud / Shutterstock.com We’ve got plenty of news to talk about th...
Conference Call and Webcast Scheduled for 1:30 p.m. PDT Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quar...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the...
After 62 recent IPOs made their way to The Russell 2000 small-cap index following the Q3 recalibrations implemented by its index provider, we showcase the healthcare stocks among the new entrants. The below discussion on newly IPO’ed healthcare constituents in the Index follo...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc. un...
Ivantis will pay $60M as well as a double-digit royalty to Glaukos (NYSE:GKOS) to settle a patent infringement lawsuit Glaukos lodged against Ivantis regarding the latter's Hydrus Microstent. $30M will be paid by December 31, 2021, with the other $30M paid by December 31, 2022. Ivan...
Ivantis to Pay $60 Million and Ongoing Double-Digit Royalty to Glaukos Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced to...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has submitted a supplemental pre-market approval (PMA) application to t...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Wells Fargo He...
Supporting the Most Robust, Diverse and Longest-Term Body of Clinical Evidence for Any MIGS Technology Multiple 5-, 6-, 7- and 8-Year Real-World Studies Published, Demonstrating Leading Efficacy & Safety Across the Entire Glaucoma Disease Spectrum Outcomes Reinforc...
News, Short Squeeze, Breakout and More Instantly...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 fin...
Shares of Glaukos Corporation (NYSE: GKOS) traded at a new 52-week high today and are currently trading at $120.11. So far today, approximately 152.81k shares have been exchanged, as compared to an average 30-day volume of 541.53k shares. Glaukos Corporation, an ophthalmic medical technology ...
2024-07-01 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...